News

GlobalData on MSN2d

RemeGen’s telitacicept achieves Phase III win in Sjögren’s syndrome

The drug met its primary endpoints in a Chinese trial, while a Phase III trial in Sjögren's syndrome is currently underway in ...
The Manila Times3d

Telitacicept Meets Primary Endpoint in Phase III Trial for Primary Sjögren's Syndrome in China

On August 13th, Remegen (688331.SH/09995.HK) announced that its global first-in-class BLyS (BAFF)/APRIL dual-target fusion ...
The Pharma Letter2d

Telitacicept hits Phase III goal for primary Sjögren's syndrome

China-based RemeGen has announced that its global first-in-class BLyS (BAFF)/APRIL dual-target fusion protein drug, ...
Fierce Biotech5d

Novartis scores double phase 3 win in Sjögren's syndrome, succeeding where rivals failed

Novartis may have abandoned one Sjögren's syndrome asset this year, but it looks like the drugmaker has a winner on its hands ...
Fierce Pharma3d

RemeGen's telitacicept meets the mark in ph. 3 Sjögren's study in China

The China-based phase 3 trial of telitacicept in primary Sjögren's syndrome (pSS) met its primary endpoint, which focused on ...

Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjögren's Disease with Telitacicept, a Dual BAFF/APRIL Inhibitor

Phase 3 results position telitacicept as potential best-in-disease profile in primary Sjögren's disease Telitacicept ...
Rheumatology Advisor1d

Ianalumab Reduces Sjögren Disease Activity in Late Stage Trials

Ianalumab is a fully human monoclonal antibody designed to deplete B cells via antibody-dependent cellular toxicity and inhibit BAFF-R-mediated signals of B cell function and survival.

Novartis Posts Encouraging Results For Sjögren's Syndrome Therapy

Good news in research for Novartis. The pharmaceutical giant has achieved the hoped-for results for Ianalumab, a candidate ...

Vor Bio Rallies On Strong Data For Autoimmune Drug Candidate

Vor Bio shares climb as RemeGen's Phase 3 study in China shows telitacicept improves disease activity in primary Sjögren's ...

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren's disease

Novartis today announced positive top-line results from its Phase III trials evaluating ianalumab (VAY736) in adults with active Sjögren's disease. Both trials met the primary endpoint of ...

A look at Venus Williams' tennis career and comeback. She's returning to the US Open at age 45

Venus Williams is back on the professional tennis tour at age 45 and will be returning to the U.S. Open next week for her ...

Ainos Receives TFDA Approval to Initiate Clinical Study of VELDONA for Primary Sjögren's Syndrome

Among these, 300 patients were treated with VELDONA®, while the remainder received placebo. The trials demonstrated that VELDONA® significantly improved dryness-related symptoms--such as dry mouth and ...